RxDoctor Payments Data

Anuj Bhatnagar, MD

Family Medicine · Millersville, MDNPI 1316253180

Payments from drug & device makers

$5,428in general payments, 2019–2025

Across 211 payments — averaging $25.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Novo Nordisk$880
  • AstraZeneca$594
  • Lilly USA, LLC$411
  • Boehringer Ingelheim$391
  • Bayer$242
  • plus $2K from 26 others

What the payments were for

  • Food & beverage$5,33198%
  • Education$972%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,428 in reported general payments places this provider in the 90th percentile of 1,193 family medicine providers in Maryland.

See all family medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$131,452
Medicare patients
279
Services billed
1,633

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide21$52,132
FarxigaDapagliflozin Propanediol22$31,651
JardianceEmpagliflozin20$30,422
TrulicityDulaglutide13$26,910
EliquisApixaban20$23,505
Atorvastatin Calcium173$3,017
Rosuvastatin Calcium94$2,119
Esomeprazole Magnesium13$1,812
Pravastatin Sodium61$1,466
Losartan Potassium113$1,411
Bupropion XlBupropion Hcl26$1,405
Escitalopram Oxalate39$1,159
Levothyroxine Sodium120$1,139
SynthroidLevothyroxine Sodium20$1,112
Famotidine49$990

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$880$52,13221 claims
AstraZenecaFarxiga$594$31,65122 claims
Boehringer IngelheimJardiance$391$30,42220 claims
Lilly USA, LLCTrulicity$411$26,91013 claims
PfizerEliquis$232$23,50520 claims
AbbVieSynthroid$1,169$1,11220 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,193 family medicine providers in Maryland.

Other family medicine in Millersville

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →